Safi Biotherapeutics Secures $4.7M to Advance Clinical Trials of Red Blood Cells
Safi Biotherapeutics, a pioneering company specializing in the development of stem-cell derived human red blood cells (mRBCs), has recently been awarded a substantial $4.7 million extension from the Department of War's Defense Health Program. This funding aims to expedite the company's efforts toward its first clinical trial, which is anticipated to begin in 2027. The initiative marks a significant step in addressing the critical demand for blood transfusion in both civilian and military contexts.
The funding will support essential activities that will enable Safi to submit an Investigational New Drug (IND) application, a necessary milestone before embarking on clinical trials. With American hospitals transfusing over 10 million units of red blood cells annually, a growing shortage of blood supply has become dire; earlier this year, the American Red Cross declared a national blood supply crisis, raising concerns about sustaining an adequate inventory for patients in need.
Safi Biotherapeutics aims to mitigate such shortages by developing a universal mRBC product that can be produced on-demand. Historically, scaling up production of mRBCs to meet clinical needs has presented considerable challenges, but Safi has successfully demonstrated that its manufacturing process can yield a fully transfusable unit from a single 10-liter bioreactor. This approach not only meets the urgent demand but also reduces reliance on traditional blood donations, often subject to fluctuations.
The CEO of Safi Biotherapeutics, Doug McConnell, outlined the implications of their work: "A blood supply that depends on donors will always be fragile, whether on the battlefield, in a hospital setting, or in the aftermath of a mass casualty event. Patients with chronic conditions, individuals undergoing surgery, and trauma victims all rely on a consistent blood supply that is prone to shortages. We believe that the future of blood must be manufactured, and our methods demonstrate that large-scale production is feasible. The funding we’ve secured directly supports our crucial work in preparing to file our IND and initiate our first clinical trial in 2027."
This latest funding from the U.S. government, facilitated by the Medical Technology Enterprise Consortium (MTEC), is a part of the Military Prototype Advancement Initiative (MPAI). With this addition, Safi has now amassed over $27 million in non-dilutive federal funding, positioning itself strategically within the growing industry focused on advanced biomanufacturing solutions.
Founded in 2020 as part of the Department of War's On-Demand Blood program, Safi Biotherapeutics leverages cutting-edge expertise in cell therapy, drawing on the skills of veterans from esteemed organizations such as DARPA and Vertex Pharmaceuticals. Their manufacturing techniques promise to provide a highly characterized mRBC product essential for both civilian healthcare facilities and military medical operations during critical times.
In addition to acute transfusion requirements, Safi is addressing chronic transfusion needs, such as those for patients suffering from sickle-cell disease. The company's product lineup is diverse, including refrigerated, cryopreserved, and freeze-dried mRBC formulations, catering to various medical applications.
As the world grapples with the challenges posed by fluctuating blood supplies, Safi Biotherapeutics stands at the forefront, pioneering a new era of manufactured blood products. Their approach not only modernizes blood transfusion practices but also aims to save countless lives, underlining the importance of steady innovation in biomedical technology. For more information on their progress and future developments, interested parties can visit their website at https://safi.bio/ or follow them on LinkedIn.
The funding will support essential activities that will enable Safi to submit an Investigational New Drug (IND) application, a necessary milestone before embarking on clinical trials. With American hospitals transfusing over 10 million units of red blood cells annually, a growing shortage of blood supply has become dire; earlier this year, the American Red Cross declared a national blood supply crisis, raising concerns about sustaining an adequate inventory for patients in need.
Safi Biotherapeutics aims to mitigate such shortages by developing a universal mRBC product that can be produced on-demand. Historically, scaling up production of mRBCs to meet clinical needs has presented considerable challenges, but Safi has successfully demonstrated that its manufacturing process can yield a fully transfusable unit from a single 10-liter bioreactor. This approach not only meets the urgent demand but also reduces reliance on traditional blood donations, often subject to fluctuations.
The CEO of Safi Biotherapeutics, Doug McConnell, outlined the implications of their work: "A blood supply that depends on donors will always be fragile, whether on the battlefield, in a hospital setting, or in the aftermath of a mass casualty event. Patients with chronic conditions, individuals undergoing surgery, and trauma victims all rely on a consistent blood supply that is prone to shortages. We believe that the future of blood must be manufactured, and our methods demonstrate that large-scale production is feasible. The funding we’ve secured directly supports our crucial work in preparing to file our IND and initiate our first clinical trial in 2027."
This latest funding from the U.S. government, facilitated by the Medical Technology Enterprise Consortium (MTEC), is a part of the Military Prototype Advancement Initiative (MPAI). With this addition, Safi has now amassed over $27 million in non-dilutive federal funding, positioning itself strategically within the growing industry focused on advanced biomanufacturing solutions.
Founded in 2020 as part of the Department of War's On-Demand Blood program, Safi Biotherapeutics leverages cutting-edge expertise in cell therapy, drawing on the skills of veterans from esteemed organizations such as DARPA and Vertex Pharmaceuticals. Their manufacturing techniques promise to provide a highly characterized mRBC product essential for both civilian healthcare facilities and military medical operations during critical times.
In addition to acute transfusion requirements, Safi is addressing chronic transfusion needs, such as those for patients suffering from sickle-cell disease. The company's product lineup is diverse, including refrigerated, cryopreserved, and freeze-dried mRBC formulations, catering to various medical applications.
As the world grapples with the challenges posed by fluctuating blood supplies, Safi Biotherapeutics stands at the forefront, pioneering a new era of manufactured blood products. Their approach not only modernizes blood transfusion practices but also aims to save countless lives, underlining the importance of steady innovation in biomedical technology. For more information on their progress and future developments, interested parties can visit their website at https://safi.bio/ or follow them on LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.